Defining Novel Molecular Pathways to Totipotency
Defining Novel Molecular Pathways to Totipotency
批准号:
9982114
负责人:
Jianlong Wang
金额:
$33.62万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-24 至 2023-06-30
关键词:
ATAC-seqAnimal ExperimentationBindingCCL3 geneCell Culture TechniquesCellsChromatinCodeComplexConceptusDataDevelopmentElementsEmbryoEmbryonic DevelopmentEndogenous RetrovirusesGenerationsGenesGenetic TranscriptionIn VitroIndividualKnowledgeLengthMessenger RNAMicroRNAsMolecularMusOrganOrganismPathway interactionsPluripotent Stem CellsProductionProteinsProteomeProteomicsRNARegulator GenesRegulatory ElementReporterReportingRoleSourceSuggestionTestingTherapeuticTimeTotipotencyTotipotentTotipotent cellTransplantationUntranslated RNAbaseembryo cellembryo stage 2embryonic stem cellgag-pol Fusion Proteinsin vitro Modelin vivonovelpluripotencyself-renewalsmall molecule inhibitorstemstem cellstranscriptomezygote
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Totipotency, a remarkable cellular plasticity of a single cell in generating a complete organism with both
embryonic and extraembryonic contribution, is essential for multicellularity and development. In mice, fully
totipotent cells exist transiently in the zygote and cleavage-stage blastomeres, although totipotent 2-cell (2C)-
like cells (2CLCs) can also arise sporadically or induced genetically in cultured embryonic stem cell (ESCs)
that are pluripotent and can only contribute to embryonic lineages. Recently, expanded potential stem cells and
extended pluripotent stem cells, collectively known as EPSCs, with totipotency features were derived and
stably cultured in vitro using two distinct sets of small molecule inhibitors. However, 2CLCs and the two EPSC
lines differ in their culture conditions, transcriptomes, and expression of core pluripotency factors, suggestive of
alternative totipotent states. 2CLCs and EPSCs represent easily accessible cell source and valuable in vitro
models for understanding totipotency, the knowledge of which will be critical to capture and stabilize the
totipotent 2CLC state, which is not currently possible. Defining molecular pathways underlying these various
totipotent cells will facilitate unraveling the complex regulatory mechanisms of totipotency and achieving the
capture/stabilization of totipotent 2CLCs. The totipotent 2CLCs were reported to reactivate transcription of
endogenous retroviruses (ERVs), in particular MERVL, whose activation has now been found to be causative
for totipotency in our preliminary studies. ZSCAN4 is also sharply expressed in 2C-stage embryo and marks
those sporadic ESCs exiting from the ESC state towards 2CLCs. By characterizing MERVL/ZSCAN4 double
reporter positive (DR+/+) ESCs, we have begun to dissect the molecular pathways underlying 2CLC
totipotency and discovered miR-344 and its direct target ZMYM2 as novel positive and negative regulators,
respectively, for MERVL activation and 2CLC totipotency. The objective of this application is to extend our
knowledge of the divergent cellular potency states in ESC culture, and define the MERVL contribution to
totipotency and explore transcriptional and post-transcriptional mechanisms underlying totipotency. We
hypothesize that 2CLCs represent an alternative totipotent state that is regulated by a novel molecular axis
encompassing the transcriptional and post-transcriptional mechanisms. We propose the following studies to
test our hypothesis. 1) Define a molecular roadmap for alternative totipotent states in EPSCs and 2CLCs. 2)
Establish the functional contribution of MERVL elements to 2CLC totipotency. We will define and distinguish
functional roles of individual MERVL elements in contributing to 2CLC totipotency. 3) Dissect the molecular
mechanism underlying 2CLC totipotency by establishing miR-344 as a new paradigm for understanding
mammalian totipotency. Understanding the molecular mechanisms that drive and induce totipotent features in
vitro is essential to understanding of how a maximum degree of cellular plasticity can be achieved and
maintained, thereby providing more options for efficient reprogramming and potential therapeutic avenues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
-
批准号:10071608
-
项目类别:
-
资助金额:$34.06万
-
财政年份:2019
-
负责人:Jianlong Wang
-
依托单位:
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
-
批准号:9922386
-
项目类别:
-
资助金额:$41.28万
-
财政年份:2019
-
负责人:Jianlong Wang
-
依托单位:
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
-
批准号:10377330
-
项目类别:
-
资助金额:$41.39万
-
财政年份:2019
-
负责人:Jianlong Wang
-
依托单位:
Defining Molecular Pathways to Expanded Puripotentiality
-
批准号:9792267
-
项目类别:
-
资助金额:$7.54万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells
-
批准号:10176171
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells
-
批准号:10401429
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Defining Novel Molecular Pathways to Totipotency
-
批准号:10428542
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control
-
批准号:9767845
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281
-
批准号:10102033
-
项目类别:
-
资助金额:$16.27万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Defining Novel Molecular Pathways to Totipotency
-
批准号:10219317
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281
-
批准号:9756422
-
项目类别:
-
资助金额:$16.88万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281
-
批准号:9903392
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Defining Novel Molecular Pathways to Totipotency
-
批准号:10102035
-
项目类别:
-
资助金额:$26.41万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Oct4 and epigenetic regulation of stem cell pluripotency
-
批准号:8305470
-
项目类别:
-
资助金额:$31.87万
-
财政年份:2011
-
负责人:Jianlong Wang
-
依托单位:
Oct4 and epigenetic regulation of stem cell pluripotency
-
批准号:8185973
-
项目类别:
-
资助金额:$31.76万
-
财政年份:2011
-
负责人:Jianlong Wang
-
依托单位:
Oct4 and epigenetic regulation of stem cell pluripotency
-
批准号:8515465
-
项目类别:
-
资助金额:$30.75万
-
财政年份:2011
-
负责人:Jianlong Wang
-
依托单位:
Oct4 and epigenetic regulation of stem cell pluripotency
-
批准号:8710256
-
项目类别:
-
资助金额:$31.87万
-
财政年份:2011
-
负责人:Jianlong Wang
-
依托单位:
海外基金